We used GPA to test the significance of pleiotropy between CAD and the same 5 psychiatric disorders (eMethods in the Supplement). For each disease pair, we estimated the percentage of SNPs shared by 2 diseases and tested the significance of pleiotropy (eTable 2 in the Supplement). The European American population yielded significant evidence of CAD-MDD pleiotropy (P = 2.39 × 10−5); genome wide, 1.7% of all imputed SNPs were estimated to be associated with both CAD and MDD. Of these, rs10954732 in P450 oxidoreductase(POR[OMIM124015]) had the largest posterior probability (although not significant) of association with both traits (P = 2.59 × 10−6 for CAD; P = .02 for MDD; posterior probability, 0.70).
